Skip to main
CRBU

Caribou Biosciences (CRBU) Stock Forecast & Price Target

Caribou Biosciences (CRBU) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Caribou Biosciences is projected to have a total market value of $837M with a 12-month price objective of $9 per share. This is based on a discounted cash flow approach with a 10% discount rate and a 1.0% terminal growth rate. The company has a favorable outlook with a 60% probability of approval for its lead assets and a 35% probability of approval for its other pipeline candidates. However, there are risks including negative clinical results, delays in advancing candidates, failure to achieve favorable results, regulatory approval challenges, competition, and long-term dilution risk.

Bears say

Caribou Biosciences is facing a negative outlook due to its heavy reliance on one main product, Vispacabtagene regedleucel, and lack of diversification. Additionally, the company has a high level of debt, with a current ratio of 2.2, which could put strain on its financial stability in the future. The change in fair value of the MSKCC payment liability also adds uncertainty to the company's financial situation.

Caribou Biosciences (CRBU) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Caribou Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Caribou Biosciences (CRBU) Forecast

Analysts have given Caribou Biosciences (CRBU) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Caribou Biosciences (CRBU) has a Strong Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Caribou Biosciences (CRBU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.